Anti-PON1 Clone KRJ1 (1 mg) -  Log in for Price

Anti-PON1 Clone KRJ1 (1 mg)

Catalog# 0801095
Product Information:
    • Volume: 1mg
    • Units/Pack: 1
    • Storage Condition: -10°C or below
    • Hazardous Information: Non-Infectious
    • Target: Does not apply

Determine the presence of arylesterase/paraoxonase (PON1) enzyme.

PON1 (arylesterase/paraoxonase) is a polymorphic enzyme closely associated with high-density lipoproteins (HDL). It is located on chromosome 7 along with 2 other paraoxanase genes, PON2 and PON3. It is a 355 amino acid, 43 kDa glycoprotein produced in the liver and secreted into the bloodstream. Gene polymorphisms occur in both coding and noncoding regions. Two major polymorphisms in the coding region are L55M and Q192R. Q192R polymorphisms result in three major functional phenotypes Q/Q, Q/R and RR. PON1 hydrolyses organophosphates and prevents the oxidation of low-density lipoproteins (LDL). It may inhibit the progression of atherosclerosis by inhibition of LDL oxidation. Levels of PON1 in serum vary among individuals and are decreased in chronic renal failure, liver cirrhosis, diabetes, peripheral neuropathy, and familial hypercholesterolemia.

What's Included: One 1 mg vial of Anti-PON1 (clone KRJ1) in phosphate-buffered saline (PBS). Supplier Certificate of Analysis (CoA) is included with product shipment.

  • 1 mg vial of Anti-PON1 (clone KRJ1)
  • Antibody in phosphate-buffered saline (PBS) matrix
  • Store at -10°C or below

PON1 (arylesterase/paraoxonase) is a polymorphic enzyme closely associated with high-density lipoproteins (HDL). It is located on chromosome 7 along with 2 other paraoxanase genes, PON2 and PON3. It is a 355 amino acid, 43 kDa glycoprotein produced in the liver and secreted into the bloodstream. Gene polymorphisms occur in both coding and non-coding regions. Two major polymorphisms in the coding region are L55M and Q192R. Q192R polymorphisms result in three major functional phenotypes Q/Q, Q/R and RR. PON1 hydrolyses organophosphates and prevents the oxidation of low-density lipoproteins (LDL). It may inhibit the progression of atherosclerosis by inhibition of LDL oxidation. Levels of PON1 in serum vary among individuals and are decreased in chronic renal failure, liver cirrhosis, diabetes, peripheral neuropathy, and familial hypercholesterolemia.

These products are supplied for research purposes only. It is not intended for use in the diagnosis or prognosis of disease, or for screening and may not be used as a confirmatory test in diagnostic situations. Propagation or commercialization are prohibited without prior written consent from Antylia Scientific.

The suitability and performance characteristics should be determined by your laboratory for each intended usage.

Welcome To